NCT05875701View on ClinicalTrials.gov

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

November 11, 2023

Study Completion Date

November 11, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

NVX-CoV2373

1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

BIOLOGICAL

SARS-CoV-2 rS antigen/Matrix-M Adjuvant

1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

Trial Locations (5)

75093

Research Your Health, Plano

76135

Benchmark Research, Fort Worth

78229

Tekton Research, San Antonio

78705

Benchmark Research, Austin

78747

Tekton Research, Austin

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT05875701 - Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | Biotech Hunter | Biotech Hunter